7654465111

List of Trials

Send Us A Message

Have questions for us? Contact us to find out more.

  • This field is for validation purposes and should be left unchanged.

Lymphoma

March 1, 2019

  • LAM Therapeutics-LAM-002A-NHL-CLN01-A Phase 1 dose escalation study of the safety and pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) administered orally in subjects with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma